Should You Take Statins After 70?
If you're 70 or older, a statin is worth considering when your chance of a first major cardiovascular event is high enough to make daily medication worth it. The new STAREE atorvastatin trial strengthens that case, but it doesn't turn age itself into a reason to start. It found fewer events in a broad endpoint that included cardiovascular death, nonfatal heart attack, stroke, and coronary revascularization. The reduction was driven mainly by fewer heart attacks and coronary procedures. It did not extend disability-free survival. So the useful question is personal: how much event risk are you trying to prevent?
The Statins in Reducing Events in the Elderly (STAREE) trial changes a decision that used to be made from partial evidence. Trials in younger and mixed-age adults showed fewer vascular events with statins, but older adults without known cardiovascular disease were thinly represented. STAREE asked the cleaner question: in community-dwelling adults 70 or older, without cardiovascular disease, diabetes, or dementia, does atorvastatin reduce a first major cardiovascular endpoint event and help preserve survival free of dementia or persistent disability? The answer split. Cardiovascular events fell. Disability-free survival did not.
The Evidence Gap Before STAREE
Before STAREE, the best randomized evidence generally favored statins, but it had a blind spot. The Cholesterol Treatment Trialists' individual-participant meta-analysis pooled 28 statin trials and found major vascular events fell by about a fifth for each 1 mmol/L lower LDL cholesterol across age groups. But the authors also said there was less direct evidence for adults older than 75 who did not already have vascular disease. That is exactly where the decision is hardest: healthy enough to prevent, old enough that the next event is no longer theoretical.
Observational studies filled some of the empty space, but they could not settle it. A large U.S. veterans cohort linked new statin use at 75 or older with lower all-cause and cardiovascular mortality. A Catalan cohort of adults 75 and older found no clear benefit in those without diabetes. Both can be true, because those who start or keep a preventive drug may differ from those who don't in ways records can't fully capture.
| Evidence | What it found | What it cannot settle |
|---|---|---|
| STAREE | In a randomized older-adult primary-prevention trial, atorvastatin lowered the composite cardiovascular endpoint but did not lengthen disability-free survival. | Whether the same benefit applies to frail adults, adults with dementia or diabetes, or people in their late 80s and 90s. |
| Pre-STAREE randomized meta-analyses | Statins lowered major vascular events across adult age groups, with the weakest direct evidence in primary prevention after 75. | A clear mortality benefit for healthy adults over 75 starting a statin before any known vascular disease. |
| Observational studies | Some large cohorts linked statin use with fewer events or deaths, while one cohort of adults 75 or older without diabetes found no clear benefit. | Cause and effect, because prescribing and adherence track with baseline health. |
What the 30% Figure Means
STAREE randomized 9,971 adults to atorvastatin 40 mg daily or placebo. The reported relative drop in the primary cardiovascular endpoint was about 30%.
The endpoint was broader than heart attack and stroke. The NEJM article defines it as cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization. The clean statement is that atorvastatin lowered a composite cardiovascular endpoint. It is too loose to say it proved a 30% cut in heart attacks and strokes alone.
The published component results support that caution: the benefit was driven mainly by fewer myocardial infarctions and coronary revascularizations. Stroke was not clearly reduced, and cardiovascular death was similar between groups.
That distinction matters because a composite can be driven by one component more than another. A prevented coronary procedure is still a real outcome, but it isn't the same as a prevented stroke. If you're deciding whether to take a pill for years, the kind of event prevented matters as much as the relative percentage.
The other primary endpoint was survival free of dementia and persistent physical disability. The composite of death, dementia, or persistent physical disability was similar between groups. Serious adverse events were reported at 2.7% in both groups. The published results also reported more musculoskeletal, hepatobiliary, and diabetes-related adverse events with atorvastatin.
The Decision Is About Starting Risk
A relative reduction isn't a personal answer. If your untreated risk is high, a 30% relative cut can mean a meaningful chance of avoiding the one event you most want to avoid. If your untreated risk is low, the same relative cut can mean years of medication for a small chance of direct benefit. The drug didn't change. The starting risk did.
That is why age alone is the wrong rule in both directions. STAREE does not support starting solely because you crossed 70. It also makes avoiding or discontinuing an otherwise tolerated statin solely because of age less defensible if your risk is high and you expect to live long enough to benefit.
Guidelines show the tension. The March 2026 multisociety American Heart Association and American College of Cardiology dyslipidemia guideline says LDL-C-lowering pharmacotherapy can be considered after age 75 with lifestyle interventions. The USPSTF recommendation dated August 23, 2022 says evidence is insufficient for starting a statin at 76 or older. STAREE is stronger than the evidence the USPSTF had in 2022, but it doesn't remove the need to weigh baseline risk, frailty, drug interactions, and your tolerance for daily medication.
If you've already had a heart attack, stroke, or known vascular disease, this is a different question. The older randomized evidence is stronger after an event than before one. STAREE is about starting a statin before cardiovascular disease is clinically evident.
The Safety Signal Is Reassuring, But Not Empty
The safety signal in STAREE matters because side effects are part of this choice. Serious adverse events were the same in both groups. Side effects can still happen. The atorvastatin label lists age 65 or older, renal impairment, uncontrolled hypothyroidism, interacting drugs, and higher dose as factors that raise muscle risk, and STAREE reported more musculoskeletal, hepatobiliary, and diabetes-related adverse events with atorvastatin.
Prior reviews put that in context. The 2022 USPSTF evidence review found no clear rise in serious adverse events, muscle pain, or diabetes overall in primary-prevention trials. The 2021 BMJ analysis found a small increase in self-reported muscle symptoms and some uncommon adverse events, while concluding that the average cardiovascular benefit was larger than those risks. A 2026 double-blind trial meta-analysis did not support a causal link between statins and cognitive impairment. The practical judgment is not that statins are risk-free. Risk depends on baseline muscle and glucose risk, kidney and thyroid status, and interacting medicines.
What Would Change the Answer
The details that would most change the answer are longer follow-up for disability, dementia, and mortality; replication in less selected adults, including frailer people and those with more multimorbidity; and results from PREVENTABLE, the large U.S. trial in adults 75 and older. For now, STAREE strengthens the case that statins can prevent first cardiovascular events after 70. It does not make a statin automatic. It makes the decision worth taking seriously when your cardiovascular risk is meaningfully elevated.